Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Dandekar G.
In der Rubrik Zeitschriften haben wir 2 Beiträge für Sie gefunden
-
MerkenThree-dimensional in vitro Tumor Models as an Alternative for Animal Models in Preclinical Studies
Rubrik: Übersichten
(Treffer aus pharmind, Nr. 04, Seite 675 (2013))
Stratmann A | Dandekar G | Nietzer S
Three-dimensional in vitro Tumor Models as an Alternative for Animal Models in Preclinical Studies / Part 2*Part 1 see Pharm. Ind. 2013;75(3):485-489. · Stratmann A, Dandekar G, Nietzer S · Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Würzburg, Germany
Cancer Cell lines Drug screening In vitro model Tissue engineering Tumor model The limits of tumor spheroids led to many attempts to provide a 3D culture setting with advanced architecture and an improved context for coculture by introducing an element providing extracellular structure. Such elements are called either matrices or scaffolds. For standardization purposes, it has been proposed to refer to hydrogels as matrices, and to cellular solids as scaffolds. [ 75 ]. Both are generally composed of extracellular matrix components, since these have been shown to maintain the original cell function in vitro. Next to gels [ 76 ], ...
-
MerkenThree-dimensional in vitro Tumor Models as an Alternative for Animal Models in Preclinical Studies
Rubrik: Übersichten
(Treffer aus pharmind, Nr. 03, Seite 485 (2013))
Stratmann A | Dandekar G | Nietzer S
Three-dimensional in vitro Tumor Models as an Alternative for Animal Models in Preclinical Studies / Teil 1 · Stratmann A, Dandekar G, Nietzer S · Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Würzburg, Germany
Cancer Cell lines Drug screening In vitro model Tissue engineering Tumor model For over 60 years, human cancer is being investigated by using various in vivo or in vitro models [ 1 , 2 ]. In 1955, the US National Cancer Institute (NCI) started the first large-scale program for drug discovery, during which the effect of various substances on mouse lymphoma models was tested in order to detect new chemotherapeutic agents. Drugs detected or developed during this program, such as anti-mitotic vinca alkaloids, actinomycin D and platinum salts, are still commonly used today [ 1 ]. Few years later, in ...
